This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim GmbH
Drug Names(s): BI 6727
Description: BI 6727 is a novel highly potent and selective inhibitor of Polo-like kinase 1 (Plk1), a key regulator of cell cycle progression. BI 6727 is a second generation dihydropteridinone derivative. Polo-like kinase belongs to a family of serine/threonine kinases with critical involvement in cell growth and differentiation in various species. Up to 80% of human tumors of various origin express high levels of PLK transcripts, whereas the according mRNA is mainly absent from surrounding healthy tissue. Polo-like kinase expression is associated with poor prognosis in some tumor types. Polo-like kinase inhibitors interfere with different stages of mitosis, with centrosome maturation, spindle formation, chromosome separation and cytokinesis. They induce mitotic chaos and severe pertubation of the cell cycle, ultimately leading to cancer cell death.
Additional information available to subscribers only: